Impact of Multiple Doses of BAY63-2521 on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Patients With Interstitial Lung Disease (ILD) Associated Pulmonary Hypertension (PH)

2023-507526-17-00 Protocol 12916 Therapeutic exploratory (Phase II) Ended

Start 13 May 2008 · End 3 Jul 2025 · Status Ended · 1 EU/EEA countries · 2 sites · Protocol 12916

Overview

Sponsor-declared trial summary

Phase Therapeutic exploratory (Phase II)
Status Ended
Participants planned 1
Countries 1
Sites 2

"Patients with interstitial lung disease associated pulmonary hypertension"

Key facts

Sponsor
Bayer AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Cardiovascular Diseases [C14]
Trial duration
13 May 2008 → 3 Jul 2025
Decision date (initial)
2024-02-05
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2023-507526-17-00
EudraCT number
2007-003928-37
ClinicalTrials.gov
NCT00694850

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

"Patients with interstitial lung disease associated pulmonary hypertension"

VersionLevelCodeTermSystem organ class
21.1 PT 10037400 Pulmonary hypertension 100000004855

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Bayer AG

Sponsor organisation
Bayer AG
Address
Kaiser-Wilhelm-Allee 1, Wiesdorf Wiesdorf
City
Leverkusen
Postcode
51373
Country
Germany

Scientific contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Public contact point

Organisation
Bayer AG
Contact name
Therapeutic Area Head

Locations

1 EU/EEA country · 2 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 1 2
Rest of world 0

Investigational sites

Germany

2 sites · Ended
Medizinische Hochschule Hannover
Klinik für Pneumologie und Infektiologie, Carl-Neuberg-Strasse 1, Gross Buchholz, Hanover
Klinikum der Universitaet Muenchen AöR
Medizinische Klinik und Poliklinik V, Marchioninistrasse 15, Hadern, Munich

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2008-05-13 2025-07-03 2008-08-02 2009-02-16

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-01-19 Germany Acceptable
2024-01-24
2024-02-05
2 SUBSTANTIAL MODIFICATION SM-1 2024-06-11 Germany Acceptable 2024-07-05
3 NON SUBSTANTIAL MODIFICATION NSM-1 2024-08-05 Germany Acceptable 2024-08-05
4 NON SUBSTANTIAL MODIFICATION NSM-2 2024-11-15 Germany Acceptable 2024-11-15
5 SUBSTANTIAL MODIFICATION SM-2 2025-03-05 Germany Acceptable
2025-04-09
2025-04-17